AMXT 1501 Dicaprate

PreclinicalSmall molecule

AMXT 1501 Dicaprate is one of 11 small molecule programs targeting Atypical Teratoid/Rhabdoid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atypical Teratoid/rhabdoid TumorRecruiting

Melanoma (skin Cancer)Recruiting

Atypical Teratoid/rhabdoid TumorPreclinical

Recruiting

Melanoma (skin Cancer)Preclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Atypical Teratoid/rhabdoid Tumor

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

1 2

Velcade

SShilpa Grover, MD, MPH

Phase 2

1 3

Paxalisib

KKazia Therapeutics Limited

Phase 2

1 4

Tecentriq

Roche

Preclinical

1 5

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Preclinical

1 6

Tiragolumab

Roche

Preclinical

1 7

AMXT 1501 Dicaprate

AAminex Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Melanoma (skin Cancer)

NCT07287917

Q2 2035

PreclinicalRecruiting

Atypical Teratoid/rhabdoid Tumor

NCT06465199

Clinical

Trials by Indication[1]

Melanoma (Skin Cancer)1 trial

A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies

Recruiting·AAminex Therapeutics, Inc.·Preclinical·NCT07287917·92 enrolled

Atypical Teratoid/Rhabdoid Tumor1 trial

A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas

Recruiting·MMilton S. Hershey Medical Center·Preclinical·NCT06465199·265 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AMXT 1501 Dicaprate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMXT 1501 Dicaprate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMXT 1501 Dicaprate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aminex Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAminex Therapeutics, Inc.

AMXT 1501 Dicaprate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2035

Trials by Indication[1]

Melanoma (Skin Cancer)1 trial

Atypical Teratoid/Rhabdoid Tumor1 trial

References

Drug Info

Quick Facts

Related News